Piceatannol

Anti-inflammatory, immunomodulatory and antiproliferative agent. Inhibits p56lck and syk protein tyrosine kinases and inhibits TNF-induced NF-κB activation and gene expression. Synthesis results from conversion of resveratrol by cytochrome P450 1B1.(In Vitro):Piceatannol is a resveratrol metabolite.SYK inhibitor Piceatannol (3.125, 6.25, 12.5, 25, and 50 μM; 72 hours) inhibits cell growth of six diffuse large B cell lymphomas (DLBCL) cell lines (SUDHL-6, U2392,DOHH2,Karpas 422, VAL, OCI Ly19) with IC50s of 18 μM, 25 μM, 37 μM, 48 μM, >50 μM and >50 μM, respectively.(In Vivo):Piceatannol (10, 20, and 40 mg/kg) inhibits the pulmonary edema and reduces the infiltration of inflammatory cells induced by lipopolysaccharide.Piceatannol (10, 20, and 40 mg/kg) alleviates the myeloperoxidase activity and inhibits the production of iNOS and COX-2 expressions in lung tissuesinduced bylipopolysaccharide.Piceatannol (10, 20, and 40 mg/kg; intraperitoneally 1 h) treatment alleviates inflammatory response by inhibiting the activation of TLR/NF-κB signaling pathway in lung tissues during acute lung injury (ALI) induced by LPS.